Clinical Trial Update: Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a vaccine therapy with or without cyclophosphamide in patients with recurrent or refractory plasma cell myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasma Cell Myeloma

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-12-16